Yuankun Cai

Prof. Dr. Yuankun Cai

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
XWXin Wang
Xin Wang
TYTao Ye
Tao Ye
WCWen-Jie Chen
Wen-Jie Chen
YLYou Lv
You Lv
ZHZong Hao
Zong Hao
YCYuankun Cai
Yuankun Cai
Structural shift of gut microbiota during chemo-preventive effects of epigallocatechin gallate on colorectal carcinogenesis in mice

8 April 2022 in Nanomedicine
Verified
Journal Article
Open access
JSJiamen Shen
Jiamen Shen
JDJiatian Dong
Jiatian Dong
FSFeng Shao
Feng Shao
JZJiaying Zhao
Jiaying Zhao
LGLifeng Gong
Lifeng Gong
YCYuankun Cai
Yuankun Cai
Aim: To investigate the anticancer effects and action mechanism of graphene oxide (GO) in colorectal cancer (CRC). Materials & methods: Anticancer effects and mechanisms of GO in CRC were investiga... Graphical abstract

28 April 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
YCYuankun Cai
Yuankun Cai
ZLZheng Liu
Zheng Liu
CJChenguang Jia
Chenguang Jia
JZJingwei Zhao
Jingwei Zhao
SCSongshan Chai
Songshan Chai
NXNan Xiong
Nan Xiong
Background: Sex differences in the outcomes of patients with aneurysmal subarachnoid hemorrhage (aSAH) remain controversial. The aim of this study was to evaluate sex differences in the outcomes of patients with aSAH.Method: This study retrospectively analyzed the clinical data of consecutive patients with aSAH, admitted to the Department of Neurosurgery, Wuhan University Zhongnan Hospital, from May 1, 2020 to December 31, 2020. The modified Rankin Scale (mRS) score was used to evaluate the prognosis of patients at discharge. Outcome indicators included cerebral ischemia, hydrocephalus, and mRS ≥ 2 at discharge.Results: The majority (65%) of the 287 patients with aSAH included in the study were females. Patients were divided into female (n = 184) and male (n = 99) groups; the female patients were significantly older than the male patients (61.3 ± 8.5 years vs. 60.0 ± 8.5 years, p = 0.032). The incidence of comorbidities (hypertension, diabetes, and heart disease) was higher in the female group than in the male group, but the difference was not statistically significant. Although more female patients than male patients underwent endovascular treatment, there was no statistical difference in the treatment approach between the two groups. Comparison of post-operative complications and mRS scores at discharge revealed that the rate of cerebral ischemia and mRS ≥ 2 at discharge were significantly higher among female patients than among male patients. Moreover, this difference persisted after propensity adjustment for age and treatment approach. Analysis of risk factors for poor prognosis at discharge in both pre- and post-adjustment patients revealed cerebral ischemia and high mFisher score (mFisher = 3/4) to be independent risk factors.Conclusion: Female patients with aSAH have a worse prognosis than male patients, and this difference may be because women are more susceptible to cerebral ischemia.

1 February 2014 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
WHWang Huipeng
Wang Huipeng
GLGong Lifeng
Gong Lifeng
GCGe Chuang
Ge Chuang
ZJZhao Jiaying
Zhao Jiaying
YCYuankun Cai
Yuankun Cai
Objective: The aim of this study was to analyze the differences in the intestinal composition between normal individuals and colon cancer patients. Methods: To establish the criteria for screening a normal individual for colon cancer, human colonic biopsies were obtained at routine colonoscopy. For patients with colon cancer, samples were obtained from cancerous regions. For normal individuals, colonic biopsies were taken from 3 sites of large intestine (descending, transverse, and ascending colon). Thereafter, a comparison of the microbiota structure by polymerase chain reaction-denaturing gradient gel electrophoresis (PCR-DGGE) was carried out. At last, bacterial species were identified by sequencing special bands from DGGE gels and comparing data with sequence databases. Result: With PCR-DGGE, we have discovered that the diversity and richness of the bacterial community from colon cancer patient’s colonic mucosa were lower than that of the normal individual’s sample. Then, a special DGGE band was found in the colon cancer patients. After sequencing, we confirmed that it had a high level of similarity with bacteroides. Conclusions: Colon cancers are closely related with the alteration of intestinal flora such as the reduction of biodiversity and richness of the bacterial community. Furthermore, the increase in proportion of bacteroides may be directly associated with colon cancer.

19 September 2018 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
YWYibin Wu
Yibin Wu
WCWenjie Chen
Wenjie Chen
LGLifeng Gong
Lifeng Gong
CKChongwei Ke
Chongwei Ke
HWHuipeng Wang
Huipeng Wang
YCYuankun Cai
Yuankun Cai
BACKGROUND:G-protein receptor 125 (GPR125), as a transmembrane signal transducer, is involved in regulating cancer development. Although GPR125 is related with several cancers, its role in colorectal cancer (CRC) and the underlying mechanism are stil...

1 January 2017 in World Journal of Gastroenterology
Verified
Journal Article
Open access
YLYou Lv
You Lv
TYTao Ye
Tao Ye
HWHui-Peng Wang
Hui-Peng Wang
JZJia-Ying Zhao
Jia-Ying Zhao
WCWen-Jie Chen
Wen-Jie Chen
YCYuankun Cai
Yuankun Cai
To evaluate the impact of recombinant Bacteroides fragilis enterotoxin-2 (BFT-2, or Fragilysin) on colorectal tumorigenesis in mice induced by azoxymethane/dextran sulfate sodium (AOM/DSS). Recombinant proBFT-2 was expressed in Escherichia coli strain Rosetta (DE3) and BFT-2 was obtained and tested for its biological activity via colorectal adenocarcinoma cell strains SW-480. Seventy C57BL/6J mice were randomly divided into a blank (BC; n = 10), model (AD; n = 20), model + low-dose toxin (ADLT; n = 20, 10 μg), and a model + high-dose toxin (ADHT; n = 20, 20 μg) group. Mice weight, tumor formation and pathology were analyzed. Immunohistochemistry determined Ki-67 and Caspase-3 expression in normal and tumor tissues of colorectal mucosa. Recombinant BFT-2 was successfully obtained, along with its biological activity. The most obvious weight loss occurred in the AD group compared with the ADLT group (21.82 ± 0.68 vs 23.23 ± 0.91, P < 0.05) and the ADHT group (21.82 ± 0.68 vs 23.57 ± 1.06, P < 0.05). More tumors were found in the AD group than in the ADLT and ADHT groups (19.75 ± 3.30 vs 6.50 ± 1.73, P < 0.05; 19.75 ± 3.30 vs 6.00 ± 2.16, P < 0.05). Pathology showed that 12 mice had adenocarcinoma and 6 cases had adenoma in the AD group. Five mice had adenocarcinoma and 15 had adenoma in the ADLT group. Four mice had adenocarcinoma and 16 had adenoma in the ADHT group. The incidence of colorectal adenocarcinoma in both the ADHT group and the ADHT group was reduced compared to that in the AD group (P < 0.05, P < 0.05). The positive rate of Ki-67 in the ADLT group and the ADHT group was 50% and 40%, respectively, both of which were lower than that found in the AD group (94.44%, P < 0.05, P < 0.05). Caspase-3 expression in the ADLT group and the ADHT group was 45% and 55%, both of which were higher than that found in the BC group (16.67%, P < 0.05, P < 0.05). Oral administration with lower-dose biologically active recombinant BFT-2 inhibited colorectal tumorigenesis in mice.